Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 combinations in advanced colorectal cancer
NCT06717880Phase 1Recruiting
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of IBI363 in colorectal cancer (CRC) (2 cohorts). Primary endpoint: Adverse Event (AE), Treatment-Emergent AE (TEAE), Adverse Event of Special Interest (AESI) and Serious Adverse Event (SAE) up to 2 years. Started Jul 2023; status: recruiting.
02
Drugs
IBI363
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06717880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717880.